home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Targeting the Ubiquitin System for Drug Discovery

 
  April 21, 2004  
     
 


Strategic Research Institute, Park Hyatt at the Bellevue
June 21-22, 2004


Speakers scheduled include selected gusts from The Genomics Institute of the Novartis Foundation, Celgene, The National Cancer Institute at Frederick and Harvard University.
 
 
Organized by: Strategic Research Institute
Invited Speakers: With the recent clinical validation of VELCADE, the first proteasome inhibitor to be approved by the FDA for cancer therapy, interest has exploded in the ubiquitin-proteasome pathway field. In addition to cancer, research is under way for the potential of therapeutic intervention in many other disease areas such as antiviral, osteoporosis and muscular atrophy. By attending this conference, you will hear from leading industrial and academic experts and take away the latest research in the field.
 
Deadline for Abstracts: June 1. 2004
 
Registration: Register by April 30 for a special early bird rate
E-mail: info@srinstitue.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.